Capturing the stem cell paracrine effect using heparin‐presenting nanofibres to treat cardiovascular diseases

The mechanism for stem cell‐mediated improvement following acute myocardial infarction has been actively debated. We support hypotheses that the stem cell effect is primarily paracrine factor‐linked. We used a heparin‐presenting injectable nanofibre network to bind and deliver paracrine factors derived from hypoxic conditioned stem cell media to mimic this stem cell paracrine effect. Our self‐assembling peptide nanofibres presenting heparin were capable of binding paracrine factors from a medium phase. When these factor‐loaded materials were injected into the heart following coronary artery ligation in a mouse ischaemia‐reperfusion model of acute myocardial infarction, we found significant preservation of haemodynamic function. Through media manipulation, we were able to determine that crucial factors are primarily < 30 kDa and primarily heparin‐binding. Using recombinant VEGF‐ and bFGF‐loaded nanofibre networks, the effect observed with conditioned media was recapitulated. When evaluated in another disease model, a chronic rat ischaemic hind limb, our factor‐loaded materials contributed to extensive limb revascularization. These experiments demonstrate the potency of the paracrine effect associated with stem cell therapies and the potential of a biomaterial to bind and deliver these factors, pointing to a potential therapy based on synthetic materials and recombinant factors as an acellular therapy. Copyright © 2010 John Wiley & Sons, Ltd.

[1]  D. Bodine,et al.  Transplanted Adult Bone Marrow Cells Repair Myocardial Infarcts in Mice , 2001, Annals of the New York Academy of Sciences.

[2]  B. Fleischmann,et al.  Bone marrow–derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation , 2004, Nature Medicine.

[3]  M. Gnecchi,et al.  Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy , 2008, Circulation research.

[4]  Florian Tögel,et al.  Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. , 2008, American journal of physiology. Renal physiology.

[5]  Kamil Ugurbil,et al.  Oxidative capacity in failing hearts. , 2003, American journal of physiology. Heart and circulatory physiology.

[6]  J. Ingwall,et al.  Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells , 2005, Nature Medicine.

[7]  Zhi-Sheng Jiang,et al.  Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. , 2004, Cardiovascular research.

[8]  J. Schlessinger,et al.  Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. , 2000, Molecular cell.

[9]  L. Field Unraveling the mechanistic basis of mesenchymal stem cell activity in the heart. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  G. Waksman,et al.  Heparin-induced Self-association of Fibroblast Growth Factor-2 , 1997, The Journal of Biological Chemistry.

[11]  Robert G Weiss,et al.  Is the failing heart energy starved? On using chemical energy to support cardiac function. , 2004, Circulation research.

[12]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[13]  A. From,et al.  Myocardial oxygenation during high work states in hearts with postinfarction remodeling. , 1999, Circulation.

[14]  W. Baumgartner,et al.  Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. , 2002, The Annals of thoracic surgery.

[15]  M. Rubart,et al.  Adult bone marrow-derived cells do not acquire functional attributes of cardiomyocytes when transplanted into peri-infarct myocardium. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  M. Entman,et al.  Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. , 2001, The Journal of clinical investigation.

[17]  Paul D. Kessler,et al.  Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart , 2002, Circulation.

[18]  X. Qin,et al.  Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. , 2005, The Annals of thoracic surgery.

[19]  J. Hare,et al.  Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche , 2007, Nature Clinical Practice Cardiovascular Medicine.

[20]  Samuel I Stupp,et al.  Self-assembling peptide amphiphile nanofiber matrices for cell entrapment. , 2005, Acta biomaterialia.

[21]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[22]  K. Kuck,et al.  Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism? , 2005, Stem cells and development.

[23]  M. Pittenger,et al.  Mesenchymal stem cells and their potential as cardiac therapeutics. , 2004, Circulation research.

[24]  H. Ohgushi,et al.  Transplantation of Mesenchymal Stem Cells Improves Cardiac Function in a Rat Model of Dilated Cardiomyopathy , 2005, Circulation.

[25]  S. Houser,et al.  Bone marrow cells adopt the cardiomyogenic fate in vivo , 2007, Proceedings of the National Academy of Sciences.

[26]  F. Tögel,et al.  Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. , 2005, Kidney international.

[27]  Mark A Sussman,et al.  Bones of contention: marrow-derived cells in myocardial regeneration. , 2008, Journal of molecular and cellular cardiology.

[28]  Michael S. Arnold,et al.  Peptide amphiphile nanostructure-heparin interactions and their relationship to bioactivity. , 2008, Biomaterials.

[29]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Stupp,et al.  Self-Assembly and Mineralization of Peptide-Amphiphile Nanofibers , 2001, Science.

[31]  M. Klagsbrun Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. , 1992, Seminars in cancer biology.

[32]  S. Homma,et al.  Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function , 2001, Nature Medicine.

[33]  Lina A. Thoren,et al.  Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion , 2008, Nature Cell Biology.

[34]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[35]  J. Isner,et al.  Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. , 1998, Circulation.

[36]  Robert L Wilensky,et al.  A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. , 2006, European heart journal.

[37]  Z. Popović,et al.  SDF‐1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  R. Shannon,et al.  Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy , 2004, Circulation.

[39]  V. Dilsizian,et al.  Metabolic Imaging With &bgr;-Methyl-p-[123I]-Iodophenyl-Pentadecanoic Acid Identifies Ischemic Memory After Demand Ischemia , 2005, Circulation.

[40]  C. Lange,et al.  Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. , 2005, American journal of physiology. Renal physiology.

[41]  David A. Williams,et al.  Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts , 2004, Nature.

[42]  H. Taegtmeyer Cardiac metabolism as a target for the treatment of heart failure. , 2004, Circulation.

[43]  Y. Yoon,et al.  Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. , 2005, The Journal of clinical investigation.

[44]  Samuel I Stupp,et al.  Peptide-amphiphile nanofibers: A versatile scaffold for the preparation of self-assembling materials , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Fei Ye,et al.  Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. , 2004, Chinese medical journal.

[46]  Douglas L Mann,et al.  Mechanisms and models in heart failure: the biomechanical model and beyond. , 2005, Circulation.

[47]  Qing-ping Li,et al.  The roles of mesenchymal stem cells (MSCs) therapy in ischemic heart diseases. , 2007, Biochemical and biophysical research communications.

[48]  G. Sukhikh,et al.  Mesenchymal Stem Cells , 2002, Bulletin of Experimental Biology and Medicine.

[49]  Mingyao Liu,et al.  Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium , 2004, Regulatory Peptides.

[50]  Samuel I Stupp,et al.  Heparin binding nanostructures to promote growth of blood vessels. , 2006, Nano letters.

[51]  Fulvio Mavilio,et al.  Gene therapy , 1993, Nature.

[52]  David M. Bodine,et al.  Bone marrow cells regenerate infarcted myocardium , 2001, Nature.

[53]  C James Kirkpatrick,et al.  Dynamic in vivo biocompatibility of angiogenic peptide amphiphile nanofibers. , 2009, Biomaterials.

[54]  A. Caplan,et al.  Mesenchymal stem cells as trophic mediators , 2006, Journal of cellular biochemistry.

[55]  R. Burt,et al.  Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. , 2008, JAMA.